SCHEMBL5134492

SCHEMBL5134492

CCOC(=O)CCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(OC)cc1)Cc1ccc(C(=O)OC)cc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.44
FAAH O00519 5/20 0.43
KDM4E B2RXH2 2/20 0.41
HPGD P15428 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MGAM O43451 1/20 0.40
SI P14410 1/20 0.40
MGAM2 Q2M2H8 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
DHODH Q02127 1/20 0.39
ALDH1A1 P00352 2/20 0.38
GSK3B P49841 2/20 0.38
LMNA P02545 1/20 0.38
DRD2 P14416 1/20 0.37
TBXA2R P21731 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137399 0.91 GAA (0.43) GAAFAAHKDM4EHPGDMEN1
SCHEMBL5137315 0.86 C5AR1 (0.51) GAAFAAHKDM4EHPGDMEN1
SCHEMBL5138080 0.86 GAA (0.41) GAAFAAHKDM4EHPGDMEN1
SCHEMBL5137376 0.85 C5AR1 (0.42) GAAKDM4EMEN1KMT2AMGAM
SCHEMBL5134777 0.85 C5AR1 (0.53) GAAFAAHKMT2ADHODHALDH1A1
SCHEMBL4770818 0.84 TAS2R14 (0.43) GAAKDM4EHPGDMEN1KMT2A
SCHEMBL5136530 0.84 C5AR1 (0.41) MEN1KMT2A
SCHEMBL5135457 0.83 TRPM8 (0.44) GAAKDM4EHPGDMGAMSI
SCHEMBL5135950 0.82 LPAR1 (0.42) GAAKDM4EMGAMSIMGAM2
SCHEMBL5135490 0.82 SIRT2 (0.43) GAAKDM4EHPGDSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed